Abstract
Objectives
The aim of the present study was to evaluate the effectiveness of platelet-rich fibrin (PRF) as a wound-healing accelerator in patients undergoing oral bisphosphonate therapy and requiring tooth extractions.
Materials and methods
A total of 102 patients were divided into a PRF group and control group. The patients received oral bisphosphonate therapy for osteoporosis for an average of 32 months. Blood was collected and PRF was introduced into the socket of the PRF group only. Monitoring of mucosal healing was conducted for 3 months in both groups, and radiographic evaluation in the sockets was performed in the PRF group. Delayed recovery was defined as exposed bone and vulnerable granulation tissue without epithelization after 4 weeks and resolving by 8 weeks.
Results
There were no intraoperative complications, and none of the patients exhibited onset of medication-related osteonecrosis of the jaw (MRONJ). Delayed recovery was observed in 9 out of 73 control patients (12%), whereas 29 PRF patients exhibited complete epithelialization of the socket within 1 month. The prevalence of delayed recovery was significantly higher in the control group than the PRF group (P < 0.05). Multivariate logistic regression analysis revealed that risk factors and use of PRF were independent significant factors to relate to delayed recovery (P = 0.02).
Conclusions
Early epithelization was confirmed in all PRF patients. Thus, PRF may reduce the risk of delayed recovery in patients undergoing oral bisphosphonate therapy.
Clinical relevance
PRF may be useful in preventing MRONJ in patients receiving oral bisphosphonate (BP).
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ruggiero SL, Dodson TB, Fantasia J et al (2014) American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J Oral Maxillofac Surg 72:1938
Mavrokokki T, Cheng A, Stein B, Goss A (2007) Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 65(3):415–423
Urade M, Tanaka N, Furusawa K et al (2011) Nationwide survey for bisphosphonate-related osteonecrosis of the jaws in Japan. J Oral Maxillofac Surg 69(11):e364–e371
Yamazaki Y, Sato J, Kitagawa Y et al (2011) A retrospective study of the healing process after tooth extraction in patients receiving oral bisphosphonates for more than 3 years. (Japanese manuscript with English abstracts). Jpn J Oral Maxillofac Surg 57(12):658–665
Yamazaki Y, Sato J, Kitagawa Y et al (2014) A retrospective study of the healing process after tooth extraction in patients receiving oral bisphosphonates. (Japanese manuscript with English abstracts). Jpn J Oral Maxillofac Surg 60(9):514–521
Marx RE, Carlson ER, Eichstaedt RM (2009) Platelet-rich plasma: growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 85:638–646
Del Fabbro M, Gallesio G, Mozzati M (2015) Autologous platelet concentrates for bisphosphonate-related osteonecrosis of the jaw treatment and prevention. A systematic review of the literature. Eur J Cancer 51(1):62–74
Dohan EDM, Rasmusson L, Albrektsson Y (1998) Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). Trends Biotechnol 27:158–167
Mazzocca AD, McCarthy MBR, Chowaniec DM et al (2012) Platelet-rich plasma differs according to preparation method and human variability. J Bone Joint Surg Am 94:308–316
Anitua E, Alkhraisat MH, Orive G (2012) Perspectives and challenges in regenerative medicine using plasma rich in growth factors. J Control Release 157:29–38
Soydan SS, Uckan S (2014) Management of bisphosphonate-related osteonecrosis of the jaw with a platelet-rich fibrin membrane: technical report. J Oral Maxillofac Surg 72(2):322–326
Mozzati M, Arata V, Gallesio G (2012b) Tooth extraction in patients on zoledronic acid therapy. Oral Oncol 48(9):817–821
Kim JW, Kim SJ, Kim MR (2014) Leucocyte-rich and platelet-rich fibrin for the treatment of bisphosphonate-related osteonecrosis of the jaw: a prospective feasibility study. Br J Oral Maxillofac Surg 52(9):854–859
Landesberg R, Cozin M, Cremers S et al (2008) Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg 66(5):839–847
Mozzati M, Gallesio G, Arata V et al (2012a) Platelet-rich therapies in the treatment of intravenous bisphosphonate-related osteonecrosis of the jaw: a report of 32 cases. Oral Oncol 48(5):469–474
Cetiner S, Sucak GT, Kahraman SA et al (2009) Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid. J Bone Miner Metab 27(4):435–443
Curi MM, Cossolin GS, Koga DH et al (2011) Bisphosphonate-related osteonecrosis of the jaws--an initial case series report of treatment combining partial bone resection and autologous platelet-rich plasma. J Oral Maxillofac Surg 69(9):2465–2472
Longo F, Guida A, Aversa C et al (2014) Platelet rich plasma in the treatment of bisphosphonate-related osteonecrosis of the jaw: personal experience and review of the literature. Int J Dent 2014:298945
Bocanegra-Pérez S, Vicente-Barrero M, Knezevic M et al (2012) Use of platelet-rich plasma in the treatment of bisphosphonate-related osteonecrosis of the jaw. Int J Oral Maxillofac Surg 41(11):1410–1415
Dohan DM, Choukroun J, Diss A et al (2006) Platelet-rich fibrin (PRF): a second-generation platelet concentrate—part II: platelet-related biologic features. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 101:e45–e50
Choukroun J, Diss A, Simonpieri A et al (2006) Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part IV: clinical effects on tissue healing. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 101:e56–e60
Pripatnanont P, Nuntanaranont T, Vongvatcharanon S et al (2013) The primacy of platelet-rich fibrin on bone regeneration of various grafts in rabbit’s calvarial defects. I J Craniomaxillofac Surg 41(8):e191–e200
Dohan Ehrenfest DM, de Peppo GM, Doglioli P et al (2009) Slow release of growth factors and thrombospondin-1 in Choukroun’s platelet-rich fibrin (PRF): a gold standard to achieve for all surgical platelet concentrates technologies. Growth Factors 27(1):63–69
He L, Lin Y, Hu X et al (2009) A comparative study of platelet-rich fibrin (PRF) and platelet-rich plasma (PRP) on the effect of proliferation and differentiation of rat osteoblasts in vitro. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 108(5):707–713
Mozzati M, Arata V, Gallesio G (2013) Tooth extraction in osteoporotic patients taking oral bisphosphonates. Osteoporos Int 24(5):1707–1712
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
The Institutional Review Board (IRB) of Hokkaido University Hospital approved the study (012–0203).
Conflict of interest
The authors declare that they have no conflict of interest.
Funding
This work was supported by KAKENHI Grant-in Aid for Scientific Research (B) (26861695).
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
Asaka, T., Ohga, N., Yamazaki, Y. et al. Platelet-rich fibrin may reduce the risk of delayed recovery in tooth-extracted patients undergoing oral bisphosphonate therapy: a trial study. Clin Oral Invest 21, 2165–2172 (2017). https://doi.org/10.1007/s00784-016-2004-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00784-016-2004-z